Kendle Expands Coverage In Sweden

Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, announced the establishment of a new office in Uppsala, Sweden, expanding its access to patients across the Scandinavian region. Kendle's new location will provide Phase II-IV clinical development solutions for its global biopharmaceutical customers and underscores the importance of Sweden as a key region for the recruitment of clinical trial patients throughout Scandinavia. Since the Clinical Trials Directive was implemented in May 2004, 10 percent of all clinical trials in the European Union were registered in Sweden.

"Sweden's efficient approval process, high-quality data and widely-respected regulatory agency make it a consistently ideal location for the conduct of clinical trials," said Kendle's Alan J. Boyce, Vice President Global Clinical Development, Europe and Africa. "In addition, its unique public health system allows for high enrollment rates, low drop-out rates and the successful, long-term tracking of patients."

Leadership for the new operation is provided by Claes-Göran Brobäck, PhD, Director, Global Clinical Development, Europe. He is responsible for Kendle's clinical operations in Sweden, including business development, financial performance, clinical project management, human resources and facilities management. Prior to joining Kendle, Brobäck worked for another global clinical research organization as a Project Director. Before that, he spent more than 12 years with Pharmacia Ltd. (now Pfizer) in a variety of clinical research positions. In all, he brings more than 18 years of experience to his new position with Kendle. Dr. Brobäck earned his doctoral degree in neuropsychology from Uppsala University in Sweden.

Kendle's office address in Sweden is Kungsgatan 62, 753 18 Uppsala, Sweden. The telephone number is +46 18 18 66 80 and the fax number is +46 18 18 66 86.

Source: Kendle